The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monday Biotech Deal Review: September 14, 2009

B&W_BigNickelThe Monday Deal Review is back in full force this week following a Labo(u)r Day vacation last week and there’s plenty of news including more information on the MDS-Danaher transaction and plenty of other companies finding ways to raise money and keep the lights on.  Keep reading
M&A

Earlier this week we blogged about MDS Inc.‘s (TSX: MDS; NYSE: MDZ) plans to sell MDS Analytical Technologies to Danaher Corporation (NYSE: DHR).  MDS announced the meeting date (October 20) and the record date (September 14… today!) for the meeting seeking approval of the sale and also rolled out voting support agreements from shareholders totalling 23% of the common shares.  Here’s FierceBiotech’s take on the deal, noting that it’s part of  a larger play by Danaher, which is also paying $450 million for Life Technologies’ half of the Life Technologies-MDS mass spectrometry JV.

Collaboration

Nuvo Research Inc.(TSX: NRI) announced a co-operative drug development project with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany for the preclinical and clinical development of WF10, Nuvo’s immune modulating drug candidate, for Allergic Rhinitis. The Development Bank of Saxony in Germany will provide financial support for the project, which may be expanded to include support for preclinical and clinical development of WF10 as a potential treatment for Rheumatoid Arthritis.  Nuvo has a history of successful out-licensing to build on now, having sold rights to its Pennsaid product line in June.

Securities Offerings

MedMira Merrily Goes Around

MedMira Inc., (NASDAQ: MMIRF, TSX-V: MIR) completed its latest equity line draw-down, issuing 2,604,639 common shares at an average price of $0.0576.

Offerings Closed

  • Cannasat Therapeutics Inc. (TSXV: CTH) completed the second tranche of a previously announced offering of units, selling an additional 1,789,000 units at $0.10 per unit raising $178,000 in gross proceeds. The units consist of one common share and one (2-year $0.15) warrant.  The first tranche sold 7.5 million units.
  • Helix BioPharma Corp. (TSX, FSE: HBP; OTCQX: HXBPF) announced and closed a private placement of 6,625,000 units at $2.05 per unit. Units are one common share and one (3-year $2.87) warrant.  Gross proceeds were $13,581,250 and net proceeds are expected to be approximately $11.7 million.
  • Bradmer Pharmaceuticals Inc. (TSX: BMR) completed its substantial issuer bid to purchase up to 8.3 million common shares for cancellation at $0.20 per share. At the expiry of the offer on August 28, 7.5 million shares remain eligible to be purchased if received by September 2, 2009. If 7.5 million shares are bought, Bradmer will have 5.99 million shares outstanding. In that case, shareholders are advised to report if they hold more than 599,000 shares (10%).
  • BELLUS Health Inc. (TSX: BLUfound takers for C$9,687,233 of its $12 million rights offering.  It will issue a total of 52,363,419 common shares at a price of C$0.185 per share. Under the rights offering, rights were exercised to subscribe for 9,120,177 common shares at the Subscription Price for proceeds of C$1,687,233. Additionally, in accordance with the terms of the stand-by purchase agreements with Vitus Investments III Private Limited and Victoria Square Ventures Inc., BELLUS will issue 21,621,621 common shares at the Subscription Price for an aggregate of C$8,000,000.
  • Microbix Biosystems Inc. (TSX: MBX) closed the private placement that they announced a couple of weeks ago, raising a bit over $750,000 and paying 300,000 (18-month, $0.35) warrants as a finders fee.

Prof. Moneypants, May I Please Have An Extension?

Thanks again to Jacob Cawker for help with the post!

Bookmark and Share

About these ads

4 responses to “Monday Biotech Deal Review: September 14, 2009

  1. Pingback: Monday Biotech Deal Review: October 12, 2009 « The Cross-Border Biotech Blog

  2. Pingback: Monday Biotech Deal Review: October 18, 2009 « The Cross-Border Biotech Blog

  3. Pingback: Monday Biotech Deal Review: November 2, 2009 « The Cross-Border Biotech Blog

  4. Pingback: Monday Biotech Deal Review: January 4, 2010 « The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 129 other followers